Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor‐associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly through complement‐dependent cytotoxicity (CDC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin‐Yuan, Chen, Yi‐Li, Liu, Guo‐Jian, Deng, Xiang‐Nan, Cui, Yue, Tan, Jie, Dong, Xing‐Chen, Li, Hua‐Ying, Chen, Gan‐Jun, Ou, Zhi‐Min, Wang, Chun‐He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433816/
https://www.ncbi.nlm.nih.gov/pubmed/35792784
http://dx.doi.org/10.1002/2211-5463.13464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433816/
https://www.ncbi.nlm.nih.gov/pubmed/35792784
http://dx.doi.org/10.1002/2211-5463.13464

Ejemplares similares